Breaking News Instant updates and real-time market news.

FPRX

Five Prime

$29.72

0.44 (1.50%)

16:24
07/17/17
07/17
16:24
07/17/17
16:24

Five Prime starts dosing in trial evaluating FPA144 in Gastric Cancer in Japan

Five Prime Therapeutics announced the company has initiated dosing in its Phase 1 clinical trial of FPA144, an anti-FGF receptor 2b antibody, in patients with advanced gastric and gastroesophageal cancer in Japan."Gastric cancer is the sixth most common cancer by incidence globally and we estimate approximately 10% of gastric cancer patients have tumors that have FGFR2 gene amplification or overexpress FGFR2b, which are associated with significantly lower survival rates than the gastric cancer patient population as a whole," said Helen Collins, M.D., Senior Vice President and Chief Medical Officer of Five Prime. "Moreover, the observed incidence of gastric cancer is higher in Asian populations than in other populations. We believe FPA144 represents a potentially promising treatment option for this targeted patient population with high unmet need. "The number of metastatic gastric and gastroesophageal junction cancer patients eligible for front-line treatment in Japan is approximately 73,000 patients per year. Five Prime estimates approximately 7,300 patients per year could be biomarker-positive and eligible for FPA144 treatment with front-line chemotherapy. The Phase 1 open-label, dose-finding study will evaluate the safety, tolerability, pharmacokinetics and recommended dose of FPA144 in approximately 6 to 12 Japanese patients with advanced gastric or gastroesophageal cancer. Completion of this Phase 1 trial is intended to enable the inclusion of Japanese patients in potential future Phase 3 trials of FPA144 in gastric cancer. Internal non-clinical data demonstrates additivity of FPA144 to standard-of-care chemotherapy regimens. Five Prime plans to initiate a global pivotal trial of FPA144 for front-line treatment of FGFR2b-overexpressing or FGFR2 gene-amplified metastatic gastric and gastroesophageal junction cancer in combination with chemotherapy in 2018.

FPRX Five Prime
$29.72

0.44 (1.50%)

08/09/16
WELS
08/09/16
NO CHANGE
WELS
Five Prime weakness overdone, says Wells Fargo
After a trial of the OPDIVO cancer treatment of Five Prime's (FPRX) partner, Bristol Myers Squibb (BMY), showed disappointing results, Wells Fargo thinks that the nearly 9% decline in Five Prime's stock was overdone. The firm thinks that it's "premature" to determine that Merck's (MRK) Keytruda has overtaken OPDIVO. The firm believes that Five Prime's OPDIVO can redeem itself in upcoming studies, and it thinks that Five Prime's stock can advance if the actor-1 receptor is proven to be a worthwhile target ,whether or not OPDIVO is shown to be effective. The firm keeps an Outperform rating on Five Prime.
10/25/16
SBSH
10/25/16
INITIATION
Target $65
SBSH
Buy
Five Prime initiated with a Buy at Citi
Citi analyst Robyn Karnauskas started Five Prime Therapeutics with a Buy rating and $65 price target. The company has "multiple shots" on goal in various cancers, Karnauskas tells investors in a research note. She believes investors will assign higher value to the Cabiralizumab program once combo data with Opdivo is seen in 2017. The analyst sees fair value for Five Prime shares in the $65-$80 range.
03/01/17
NOMU
03/01/17
INITIATION
Target $94
NOMU
Buy
Five Prime initiated with a Buy at Nomura
Nomura initiated Five Prime with a Buy and a $94 price target.
03/24/17
COWN
03/24/17
INITIATION
COWN
Outperform
Five Prime initiated with an Outperform at Cowen
Cowen analyst Chris Shibutani initiated Five Prime (FPRX) with an Outperform saying its proprietary IO platform is underappreciated by investors and has multiple clinical readouts in 2017 provide catalysts to drive value generation. The analyst said Five Prime's $1.8B out-licensing partnership deal with Bristol Myers (BMY) for Cabiralizumab in 2015 provides validation in supporting its platform.

TODAY'S FREE FLY STORIES

UAL

United Continental

$63.93

-4.06 (-5.97%)

10:40
10/19/17
10/19
10:40
10/19/17
10:40
Hot Stocks
United Continental says Q3 involuntary denied boardings down 92% y/y »

Says employees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

VRX

Valeant

$12.10

-0.29 (-2.34%)

10:40
10/19/17
10/19
10:40
10/19/17
10:40
Options
Higher options volume in Valeant as one player banks a big profit »

Higher options volume in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

BP

BP

$38.81

0.09 (0.23%)

10:36
10/19/17
10/19
10:36
10/19/17
10:36
Hot Stocks
BP chairman Carl-Henric Svanberg announces intention to retire »

BP announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MON

Monsanto

$121.99

-0.09 (-0.07%)

, AGCO

Agco

$70.84

-0.91 (-1.27%)

10:33
10/19/17
10/19
10:33
10/19/17
10:33
Hot Stocks
Monsanto's Climate Corp announces data connectivity agreement with Agco »

The Climate Corporation,…

MON

Monsanto

$121.99

-0.09 (-0.07%)

AGCO

Agco

$70.84

-0.91 (-1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

FCEL

FuelCell

$2.13

0.09 (4.41%)

10:31
10/19/17
10/19
10:31
10/19/17
10:31
Hot Stocks
FuelCell to supply power to Navy base in Connecticut »

FuelCell Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

10:30
10/19/17
10/19
10:30
10/19/17
10:30
General news
EIA natural gas storage change for week ending October 13 »

Gas inventories 51 Bcf…

MU

Micron

$41.65

1.26 (3.12%)

10:30
10/19/17
10/19
10:30
10/19/17
10:30
Options
Active trading in Micron calls as shares slump Thursday »

Active trading in Micron…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 23

    Oct

NKE

Nike

$52.21

-0.0915 (-0.17%)

, ADDYY

adidas

$112.54

-0.08 (-0.07%)

10:29
10/19/17
10/19
10:29
10/19/17
10:29
Hot Stocks
Goldman Sachs cuts Nike rating ahead of investor day on excess inventory »

This morning, Goldman…

NKE

Nike

$52.21

-0.0915 (-0.17%)

ADDYY

adidas

$112.54

-0.08 (-0.07%)

GRPN

Groupon

$5.00

0.05 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 01

    Nov

  • 16

    Nov

ULTA

Ulta Beauty

$200.90

2.59 (1.31%)

10:29
10/19/17
10/19
10:29
10/19/17
10:29
Rumors
Rumor moving shares of Ulta Beauty »

Rumor: Ulta Beauty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:25
10/19/17
10/19
10:25
10/19/17
10:25
General news
Today's U.S. reports »

Today's U.S. reports…

UAL

United Continental

$64.26

-3.73 (-5.49%)

10:23
10/19/17
10/19
10:23
10/19/17
10:23
Technical Analysis
Technical View: United Continental falls after results and outlook »

The company reported Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

MEIP

MEI Pharma

$2.48

0.15 (6.44%)

10:23
10/19/17
10/19
10:23
10/19/17
10:23
Hot Stocks
MEI Pharma's pracinostat granted EU orphan designation »

Pracinostat was granted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$50.08

1.431 (2.94%)

10:20
10/19/17
10/19
10:20
10/19/17
10:20
Options
Notable ratio spread in Verizon as shares rally on earnings »

Notable ratio spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 01

    Nov

10:20
10/19/17
10/19
10:20
10/19/17
10:20
General news
Treasury Action: yields resumed their slide »

Treasury Action: yields…

$NSD

NASDAQ Market Internals

10:17
10/19/17
10/19
10:17
10/19/17
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

10:16
10/19/17
10/19
10:16
10/19/17
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$63.76

0.25 (0.39%)

, TEVA

Teva

$14.61

-0.01 (-0.07%)

10:15
10/19/17
10/19
10:15
10/19/17
10:15
Periodicals
Merck wins appeal to revive NuvaRing patent case against Teva, Bloomberg says »

An appeals court said a…

MRK

Merck

$63.76

0.25 (0.39%)

TEVA

Teva

$14.61

-0.01 (-0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 23

    Oct

  • 27

    Oct

  • 02

    Nov

  • 06

    Nov

  • 08

    Nov

  • 16

    Nov

  • 30

    Nov

  • 02

    Feb

ADP

ADP

$113.93

0.21 (0.18%)

10:15
10/19/17
10/19
10:15
10/19/17
10:15
Hot Stocks
Pershing Square releases additional questions for ADP »

Pershing Square Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

10:15
10/19/17
10/19
10:15
10/19/17
10:15
General news
U.S. leading economic index fell 0.2% to 128.6 in September »

U.S. leading economic…

10:15
10/19/17
10/19
10:15
10/19/17
10:15
General news
Breaking General news story  »

Week of 10/13 EIA Natural…

GS

Goldman Sachs

$240.07

-1.96 (-0.81%)

10:13
10/19/17
10/19
10:13
10/19/17
10:13
Hot Stocks
Blankfein: 'Just left Frankfurt,' 'I'll be spending a lot more time there' »

Goldman Sachs Chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

EVHC

Envision Healthcare

$40.70

0.05 (0.12%)

10:11
10/19/17
10/19
10:11
10/19/17
10:11
Periodicals
Starboard's Smith to pitch Envision Healthcare as long idea, Bloomberg says »

Starboard Value's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

NNI

Nelnet

$51.05

-0.27 (-0.53%)

10:10
10/19/17
10/19
10:10
10/19/17
10:10
Upgrade
Nelnet rating change  »

Follow-up: Nelnet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$12.30

0.4 (3.36%)

10:10
10/19/17
10/19
10:10
10/19/17
10:10
Options
Short-term call buyer in Ceaser's opens a notable new position »

Short-term call buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

MMP

Magellan Midstream

$67.56

-0.96 (-1.40%)

10:09
10/19/17
10/19
10:09
10/19/17
10:09
Hot Stocks
Magellan Midstream raises quarterly distribution to 90.5c per unit »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.